Navigation Links
ULURU Inc. Reports Third Quarter 2011 Financial Results
Date:11/15/2011

ADDISON, Texas, Nov. 15, 2011 /PRNewswire/ -- ULURU Inc. (NYSE AMEX: ULU) today announced its financial results for the third quarter ended September 30, 2011.

For the third quarter of 2011, the Company reported a net loss of $1.0 million, or $0.18 per share, compared with a net loss of $1.2 million, or $0.22 per share, for the same period last year.  For the nine months ended September 30, 2011, the Company reported a net loss of $3.2 million, or $0.55 per share, compared with a net loss of $4.7 million, or $0.87 per share, for the same period last year.  

Commenting on the financial results Kerry P. Gray, President and CEO, stated, "Revenue was lower than projected as a major distributor order of approximately $200,000 was not billed until October due to a production delay.  Revenues in the fourth quarter will expand significantly as we fill distributor orders, receive licensing payments, and increase our Altrazeal® business.  Expense continued to be contained and are in line with our financial plan."

Operating ResultsRevenues

Revenue for the third quarter of 2011 was $74,000, compared to $62,000 for the third quarter of 2010.

Revenue for the nine months ended September 30, 2011 was $229,000, compared to $528,000 for the nine months ended September 30, 2010.  The decrease of $299,000 in revenue was due primarily to a decrease of $138,000 in Aphthasol® product sales as we did not sell any Aphthasol® during the first nine months of 2011 and a decrease of $174,000 in Zindaclin® related licensing and royalty fees due to our divestiture of this product in June 2010.

Research and Development

Research and development expenses for the third quarter of 2011 were $233,000, including $17,000 in share-based compensation, compared to $296,000, including $32,000 in share-based compensation, for the third quarter of 2010.  The decrease of approximately $63,000 in research and development expenses was primarily due to lower costs for regulatory fees of $42,000 and share-based compensation of $15,000.

Research and development expenses for the nine months ended September 30, 2011 were $749,000, including $52,000 in share-based compensation, compared to $949,000, including $104,000 in share-based compensation, for the nine months ended September 30, 2010.  The decrease of approximately $200,000 in research and development expenses was primarily due to lower costs for regulatory fees of $133,000, clinical testing costs of $43,000 and scientific compensation costs of $19,000.

Selling, General and Administrative

Selling, general and administrative expenses for the third quarter of 2011 were $566,000, including $25,000 in share-based compensation, compared to $666,000, including $26,000 in share-based compensation, for the third quarter of 2010.  The decrease of approximately $100,000 in selling, general and administrative expenses was primarily due to lower costs for sales & marketing of $135,000 as a result of lower head count, reduced share-based compensation, and decreased marketing expenses.  These expense decreases were partially offset by an increase in shareholder expenses relating to investor relations consulting of $61,000.

Selling, general and administrative expenses for the nine months ended September 30, 2011 were $1.8 million, including $77,000 in share-based compensation, compared to $2.4 million, including $195,000 in share-based compensation, for the nine months ended September 30, 2010.  The decrease of approximately $626,000 in selling, general and administrative expenses was primarily due to lower costs for compensation of $162,000 as a result of lower head count and reduced share-based compensation, sales & marketing costs of $284,000, legal costs relating to our patents of $88,000, commission expense of $30,000 and legal fees of $30,000.  These expense decreases were partially offset by an increase in shareholder expenses of $56,000 relating to investor relations consulting.

Mr. Gray continued, "Significant progress was reported in the third quarter, including financing, a strategic partnership, and clinical data. We achieved an important milestone in the third quarter with the signing of a binding letter of intent for the marketing of Altrazeal® in Europe. Positive clinical data has been produced in Europe in a number of hospitals and key opinion leaders' support is being generated. Plans for producing the initial launch quantities are being developed. This agreement has significant economic benefits to the Company both in the short and longer term. Additionally, further clinical data supporting the use of Altrazeal® in accelerating healing of diabetic foot ulcers was presented at a wound care conference; this is important data as it was in combination with a removable off-loading device which is the major segment of this market. We have also continued our efforts and made advancements towards completing additional partnerships to execute our business plan."

About ULURU Inc.:ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com.  For further information about Altrazeal®, please visit our website at www.altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to future financial performance of ULURU Inc. (the "Company"), the anticipated increase in revenues in the fourth quarter of 2011, our business plan for the balance of 2011 including significant revenue growth for our products, the anticipated benefits of our marketing strategy for Altrazeal®, the positive clinical data and key opinion leader support in Europe, and the completion of additional strategic partnerships.  When used in this press release, the words "believe," "expect" and "anticipate" and similar expressions may be indicative of forward-looking statements including without limitation statements relating to the regulatory results for our products.  These statements by their nature involve substantial risks and uncertainties, certain of which are beyond the Company's control. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of an unanticipated event. Further, management cannot assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.   These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2010 and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145ULURU Inc.SUMMARY OF RESULTSSTATEMENTS OF OPERATIONS DATAThree Months Ended September 30,Nine Months Ended September 30,2011201020112010REVENUESLicense fees

$
,184$
4,370$
8,349$  150,283Royalty income

18,86123,10451,528132,473Product sales, net

48,60734,143159,132245,725Other

------------Total Revenues

73,65261,617229,009528,481COSTS AND EXPENSESCost of goods sold

11,0656,41635,545143,259Research and development

233,087295,781749,049948,960Selling, general and administrative

566,541666,2051,779,0452,405,123Amortization of intangible assets

206,454206,454612,632699,252Depreciation

75,35979,073227,665179,053Total Costs and Expenses

1,092,5061,253,9293,403,9364,375,647OPERATING (LOSS)(1,018,854)(1,192,312)(3,174,927)(3,847,166)Other Income (Expense)Interest and miscellaneous income

1,8574,8409,4855,555Interest expense

(22,545)(20,650)(48,839)(37,138)Loss on sale of intangible asset

---------( 857,839)(LOSS) Before Income Taxes(1,039,542)(1,208,122)(3,214,281)(4,736,588)Income taxes

------------NET (LOSS)$(1,039,542)$(1,208,122)$(3,214,281)$(4,736,588)Less preferred stock dividends

(462)---(462)---NET (LOSS) Allocable to Common Stockholders$(1,040,004)$(1,208,122)$(3,214,743)$(4,736,588)Basic and diluted net (loss) per common share

$   (0.18)$   (0.22)$  (0.55)$  (0.87)WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

5,928,0845,472,2885,850,9005,423,076ULURU Inc.SELECTED CONDENSED CONSOLIDATED BALANCE SHEET DATASeptember 30, 2011December 31, 2010(Unaudited)(Audited)  Cash and cash equivalents

$
,989$
41,441  Current assets

1,597,4441,996,265  Property and equipment, net

1,147,8181,375,484  Other assets

4,797,0045,648,764  Total assets

7,542,2669,020,513  Current liabilities

1,797,9891,019,597  Long term liabilities

907,994594,653  Total liabilities

2,705,9831,614,250  Total stockholders' equity

4,836,2837,406,263
'/>"/>

SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
4. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
5. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
6. ULURU Inc. Reports Second Quarter 2010 Financial Results
7. ULURU Inc. Announces Conference Call
8. ULURU Inc. Provides Altrazeal® Clinical Update
9. ULURU Inc. Reports Third Quarter 2010 Financial Results
10. ULURU Inc. to Raise $500,000 in Registered Direct Offering
11. ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... March 30, 2017  Lannett Company, Inc. (NYSE: ... made a $25 million payment against its existing revolving ... combined with the $75 million payment we made earlier ... million in annualized cash interest expense, at current rates" ... Lannett.  "Our business is solid and we continue to ...
(Date:3/30/2017)... Revenue Prospects by Product Type (Metered Dose ... Geography Respiratory Inhalers - our new study reveals trends, ... market heading? If you are involved in this sector you must ... the potential revenues streams to 2027, assessing data, trends, opportunities and ... ...
(Date:3/30/2017)... 30, 2017  Purcell Julie & Lefkowitz LLP, a class ... a potential breach of fiduciary duty claim involving the board ... ). If you are a shareholder of ... this investigation, free of charge, please visit us at: ... http://pjlfirm.com/synergy-pharmaceuticals-inc/ ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... March 30, 2017 , ... AudioEducator, ... conference “ Preventing Hospital Readmissions Through Discharge Planning ” with noted expert Sue ... ET. This conference discusses strategies to prevent readmissions in light of the most ...
(Date:3/29/2017)... ... 29, 2017 , ... During the last week of March, Chad Kawa, MD ... individuals in the local community. , Colon cancer is the second leading cause ... cancer while it is small, confined and easier to treat. If you are 50 ...
(Date:3/29/2017)... San Diego, CA (PRWEB) , ... March 29, 2017 , ... ... meningiomas(1,2), and up to 300,000 people each year develop other types of metastatic brain ... spread quickly throughout the brain(3). As efforts focus on finding more effective treatment options, ...
(Date:3/29/2017)... ... March 29, 2017 , ... Full Contact K9, an Atlanta-based ... Pet Protect Law that assists dog owners in creating legally-enforceable pet trusts for ... taking the natural next step to protect their new companion. Says Evan Dunbar, CEO ...
(Date:3/29/2017)... ... March 30, 2017 , ... CHARM CITY RUN WELCOMES MERCY MEDICAL ... that Mercy Medical Center will serve as the official title sponsor of the Baltimore ... June 25, 2017, thousands of women will walk or run the course around the ...
Breaking Medicine News(10 mins):